TY - JOUR
T1 - Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk
T2 - Subgroup Analysis of the Alliance A031203 CABOSUN trial
AU - George, Daniel J.
AU - Hessel, Colin
AU - Halabi, Susan
AU - Michaelson, M. Dror
AU - Hahn, Olwen
AU - Walsh, Meghara
AU - Picus, Joel
AU - Small, Eric J.
AU - Dakhil, Shaker
AU - Feldman, Darren R.
AU - Mangeshkar, Milan
AU - Scheffold, Christian
AU - Morris, Michael J.
AU - Choueiri, Toni K.
N1 - Funding Information:
We thank the patients, their families, the investigators and site staff, the Alliance for Clinical Trials in Oncology, the Cancer Therapy Evaluation Program (John Wright), and the study teams participating in this trial. Medical writing support was provided by Julie C. Lougheed, Ph.D. (Exelixis), with editorial assistance by Fishawack Communications Inc. (Conshohocken, PA), which was funded by Exelixis. Research reported in this publication was supported by National Institutes of Health (Award Numbers U10CA180821 and U10CA180882 [to the Alliance for Clinical Trials in Oncology], U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867), and Exelixis, Inc. (Alameda, CA). TKC is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE and Program, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at the Dana-Farber Cancer Institute. Patient treatment at Memorial Sloan Kettering Cancer Center was supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). The content is the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. For more information on support for the Alliance for Clinical Trials in Oncology, see https://acknowledgments.alliancefound.org.
Funding Information:
Daniel J. George daniel.george@duke.edu Colin Hessel Susan Halabi M. Dror Michaelson Olwen Hahn Meghara Walsh Joel Picus Eric J. Small Shaker Dakhil Darren R. Feldman Milan Mangeshkar Christian Scheffold Michael J. Morris Toni K. Choueiri Durham North Carolina USA Alameda California USA Durham North Carolina USA Boston Massachusetts USA Chicago Illinois USA Boston Massachusetts USA St. Louis Missouri USA San Francisco California USA Wichita Kansas USA New York New York USA Dana‐Farber Harvard Cancer Center Kidney SPORE and Program Exelixis Inc. Loker Pinard Funds for Kidney Cancer Research at the Dana‐Farber Cancer Institute Memorial Sloan Kettering Cancer Center Support Grant Core Grant P30 CA008748 Michael Brigham National Institutes of Health U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867 The Kohlberg Chair at Harvard Medical School and the Trust Family
Publisher Copyright:
© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.
AB - Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.
UR - http://www.scopus.com/inward/record.url?scp=85070453089&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2019-0316
DO - 10.1634/theoncologist.2019-0316
M3 - Article
C2 - 31399500
AN - SCOPUS:85070453089
SN - 1083-7159
VL - 24
SP - 1497
EP - 1501
JO - Oncologist
JF - Oncologist
IS - 11
ER -